Innovimmune awarded NIH NIAID SBIR Phase II $3 Million grant for the development of its proprietary oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases

NIAID.png

Innovimmune is awarded a $3 million, three-year (2014-2017) National Institute of Health (NIH) Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAIAD) to advance the preclinical development of proprietary First-in-Class INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Rheumatoid Arthritis, its novel proprietary oral small molecule MIF inhibitor portfolio in development for the treatment of autoimmune and rare diseases.